Parkinson’s disease is a progressive neurodegenerative disease whose main clinical manifestations are resting tremor, movement rigidity, motor slowing and gait abnormalities in the limbs. In addition, patients also have significant non-motor symptoms, such as constipation, sleep disturbance and depression. Patients with severe disease are unable to take care of themselves, which brings serious burden to the family. Deep brain electrical stimulation surgery is a new medical device to treat Parkinson’s disease through neuromodulation technology. Brain pacemaker treatment is to improve patients’ motor dysfunction by inhibiting abnormal neuronal activity at the stimulation site; alleviating side effects caused by medications; and enhancing patients’ daily living ability. The population for whom pacemaker therapy is indicated for Parkinson’s disease Patients with Parkinson’s disease can be evaluated for pacemaker surgery if they meet the following conditions 1. Diagnosed with primary Parkinson’s 2. Good response to levodopa-based drugs (Medobar and Xanax are both levodopa-based drugs) 3. Decreased efficacy/side effects such as dyskinesia 4. Knowledge of pacemaker therapy and reasonable expectations of surgical efficacy 5. Normal cognitive ability (no dementia) Efficacy of pacemaker therapy for Parkinson’s disease Significant improvement in rigidity, tremor, and dyskinesia; reduction of gait The pacemaker can significantly improve rigidity, tremor and dyskinesia; reduce gait, balance and dystonia; effectively control most of the mid-axis symptoms, such as difficulty in standing, starting, turning and rolling; significantly prolong the “on” period for 4-5 hours, and eliminate the “on” period hyperactivity; reduce the daily dose of anti-Parkinsonian drugs in some patients by In some patients, the daily dose of anti-Parkinsonian drugs can be reduced by 40%-60%, and some patients can stop taking the drugs; in the case of reducing or stopping the drugs, the side effects of the drugs can be reduced accordingly; some patients can improve their speech and writing disorders. Patients with Parkinson’s disease can be considered for a pacemaker when they have motor complications after taking medication, generally following the following principles: five years or more for the duration of the disease; up to three years earlier if the tremor is predominant and the disease is clearly Parkinson’s, if the patient has a strong desire for treatment; the current drug dosage is high and there is insufficient room for drug adjustment; the effect of drugs on symptom control is clearly diminished; and the effect of drugs on symptom control is significantly reduced. effect is significantly diminished; there are significant motor fluctuations or allodynia; and the condition has seriously affected the patient’s quality of life. In the treatment of deep brain electrical stimulation surgery, there are two reasons that affect the postoperative effect: first, the accuracy of the surgical target implantation; second, the correctness of the postoperative program control, that is, the adjustment of the pacemaker parameters. There is also a close relationship between the two. In the postoperative program control stage, in order to regulate the parameters of the pacemaker and have a good therapeutic effect, the program control surgeon must first have a comprehensive understanding of the electrode implantation target. This is because the position of the electrode implantation target is the basis for determining the stimulation site, stimulation range and parameter adjustment direction, and it also has a great influence on the postoperative program control effect.